Invivyd (IVVD) Free Cash Flow (2021 - 2025)
Invivyd posted quarterly Free Cash Flow of -$15.5 million for Q4 2025, up 58.9% year-on-year from -$9.7 million in Q4 2024, and down 87.33% on a QoQ basis from -$8.2 million in Q3 2025.
Invivyd (IVVD) has 5 years of Free Cash Flow data on file, last reported at -$15.5 million in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow rose 58.9% year-over-year to -$15.5 million; the trailing twelve-month figure through Dec 2025 stood at -$58.3 million (up 65.84% YoY), and the FY2025 full-year result was -$58.3 million, up 65.84% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$15.5 million, down from -$8.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.2 million in Q3 2025 and bottomed at -$73.3 million in Q4 2021.
- The 5-year median for Free Cash Flow is -$41.3 million (2024), against an average of -$40.5 million.
- The widest annual swing landed in 2022, when Free Cash Flow slumped 148.72%; it then surged 79.91% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$73.3 million in 2021, then soared by 33.67% to -$48.6 million in 2022, then retreated by 21.86% to -$59.2 million in 2023, then surged by 36.52% to -$37.6 million in 2024, then soared by 58.9% to -$15.5 million in 2025.
- The last three Free Cash Flow figures came in at -$15.5 million (Q4 2025), -$8.2 million (Q3 2025), and -$13.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -15.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.46 Mn |
| Dec 31, 2025 | -15.46 Mn |
| Sep 30, 2025 | -8.25 Mn |
| Sep 30, 2025 | -8.25 Mn |
| Jun 30, 2025 | -13.31 Mn |
| Jun 30, 2025 | -13.31 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -37.61 Mn |
| Dec 31, 2024 | -37.61 Mn |
| Sep 30, 2024 | -41.07 Mn |
| Sep 30, 2024 | -41.07 Mn |
| Jun 30, 2024 | -41.60 Mn |
| Jun 30, 2024 | -41.60 Mn |
| Mar 31, 2024 | -50.35 Mn |
| Mar 31, 2024 | -50.35 Mn |
| Dec 31, 2023 | -59.24 Mn |
| Dec 31, 2023 | -59.24 Mn |
| Sep 30, 2023 | -35.35 Mn |
| Sep 30, 2023 | -35.35 Mn |
| Jun 30, 2023 | -37.38 Mn |
| Jun 30, 2023 | -37.38 Mn |
| Mar 31, 2023 | -41.81 Mn |
| Mar 31, 2023 | -41.81 Mn |
| Dec 31, 2022 | -48.62 Mn |
| Dec 31, 2022 | -48.62 Mn |
| Sep 30, 2022 | -56.62 Mn |
| Sep 30, 2022 | -56.62 Mn |
| Jun 30, 2022 | -57.41 Mn |
| Jun 30, 2022 | -57.41 Mn |
| Mar 31, 2022 | -59.05 Mn |
| Mar 31, 2022 | -59.05 Mn |
| Dec 31, 2021 | -73.30 Mn |
| Dec 31, 2021 | -73.30 Mn |
| Sep 30, 2021 | -54.21 Mn |
| Sep 30, 2021 | -54.21 Mn |
| Jun 30, 2021 | -33.57 Mn |
| Jun 30, 2021 | -33.57 Mn |
| Mar 31, 2021 | -23.74 Mn |
| Mar 31, 2021 | -23.74 Mn |